---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-201717"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T14:37:06.632977+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tarsus prices $100M public offering of 5.71M shares at $17.50/share

## Summary
- Net proceeds expected to be ~$93.6M after underwriting discounts and offering expenses.
- Underwriters granted 30-day option to purchase up to an additional 857,142 shares.
- Joint book-running managers: Goldman Sachs, BofA Securities, Guggenheim Securities, Oppenheimer.
- Offering expected to close on August 4, 2023, subject to customary closing conditions.

## SEC filing metadata
- accession: 0001193125-23-201717
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000119312523201717/0001193125-23-201717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000119312523201717/d596862d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-201717
- JSON: https://secwatch.observer/filing/0001193125-23-201717.json
- Plain text: https://secwatch.observer/filing/0001193125-23-201717.txt

## Key facts
- Material Agreements
  Tarsus Pharmaceuticals, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters valued at approximately $93.6 million (effective 2023-08-01).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters
  - Value: approximately $93.6 million
  - Effective: 2023-08-01
  source text: On August 1, 2023, Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Guggenheim Securities, LLC, acting as representatives of the underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 5,714,285 shares of the Company’s common stock, par value $0.0001 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312523201717/0001193125-23-201717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.